ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.90
-0.22%
Dow Jones
40,954.48
1.85%
Gold vs US Dollar
2,467.265
1.86%
Brent Oil
83.315
-1.22%
Bitcoin
64,345.81
-0.78%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) News

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateTimeSourceHeadlineSymbolCompany
11/10/200523:06PR Newswire (US)Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/09/200514:00PR Newswire (US)Allos Therapeutics to Present at the UBS Global Life Sciences ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/09/200514:02PR Newswire (US)Allos Therapeutics to Present at the Bear Stearns Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200514:00PR Newswire (US)Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients ReceiNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/08/200514:01PR Newswire (US)Allos Therapeutics Reports Second Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/200520:28PR Newswire (US)Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug SubstanceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/05/200523:46PR Newswire (US)Allos Therapeutics Announces Stockholder Approval of Share ExchangeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/05/200514:00PR Newswire (US)Allos Therapeutics to Present at the Needham & Company Biotechnology ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200514:01PR Newswire (US)Allos Therapeutics Reports First Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/03/200511:00PR Newswire (US)Allos Therapeutics to Present at SG Cowen's Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200511:02PR Newswire (US)Allos Therapeutics Reports 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200511:00PR Newswire (US)Allos Therapeutics Announces $50 Million FinancingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/01/200513:00PR Newswire (US)Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/01/200513:01PR Newswire (US)Allos Therapeutics Announces Expansion of ENRICH Trial Into EuropeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/12/200413:00PR Newswire (US)Allos Therapeutics Licenses New Cancer CompoundNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/12/200416:38PR Newswire (US)Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer SymposNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200411:00PR Newswire (US)Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200413:01PR Newswire (US)Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXIINASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/11/200421:30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/200421:30PR Newswire (US)Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200414:00PR Newswire (US)Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/10/200414:00PR Newswire (US)Allos Therapeutics to Present at Rodman & Renshaw ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/10/200414:00PR Newswire (US)Allos Therapeutics Appoints Marc Graboyes as Vice President, General CounselNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/10/200422:30PR Newswire (US)Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized StudyNASDAQ:ALTH
04/10/200420:30PR Newswire (US)Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/08/200421:23PR Newswire (US)Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/08/200413:45PR Newswire (US)Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/08/200412:00PR Newswire (US)Allos Therapeutics Reports Second Quarter 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/07/200414:00PR Newswire (US)Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/200414:01PR Newswire (US)Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and EuropeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Your Recent History

LSE
SMDR
Salamander Energy
LSE
WWH
Worldwide Healthcare
LSE
ISAC
Ishr Acwi
USOTC
UILCF
Singapore LD (PK)
AMEX
AREN
Arena
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved